| Triple negative breast cancer: a brief review of its characteristics and treatment options CL Griffiths, JL Olin Journal of pharmacy practice 25 (3), 319-323, 2012 | 144 | 2012 |
| Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes H Masuda, TM Brewer, DD Liu, T Iwamoto, Y Shen, L Hsu, JS Willey, ... Annals of oncology 25 (2), 384-391, 2014 | 134 | 2014 |
| Does optical coherence tomography identify arterial healing after stenting? An in vivo comparison with histology, in a rabbit carotid model F Prati, M Zimarino, E Stabile, G Pizzicannella, T Fouad, R Rabozzi, ... Heart 94 (2), 217-221, 2008 | 122 | 2008 |
| The MD Anderson manual of medical oncology HM Kantarjian, RA Wolff, CA Koller McGraw Hill Professional, 2011 | 107 | 2011 |
| Novel antibody–drug conjugates for triple negative breast cancer A Nagayama, N Vidula, L Ellisen, A Bardia Therapeutic advances in medical oncology 12, 1758835920915980, 2020 | 106 | 2020 |
| Inflammatory breast cancer: what to know about this unique, aggressive breast cancer A Menta, TM Fouad, A Lucci, H Le-Petross, MC Stauder, WA Woodward, ... Surgical Clinics 98 (4), 787-800, 2018 | 99 | 2018 |
| Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system TM Fouad, AMG Barrera, JM Reuben, A Lucci, WA Woodward, ... The Lancet Oncology 18 (4), e228-e232, 2017 | 98 | 2017 |
| Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis TM Fouad, T Kogawa, DD Liu, Y Shen, H Masuda, R El-Zein, ... Breast cancer research and treatment 152, 407-416, 2015 | 93 | 2015 |
| Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer M Mego, H Gao, EN Cohen, S Anfossi, A Giordano, T Sanda, TM Fouad, ... Journal of Cancer 7 (9), 1095, 2016 | 92 | 2016 |
| Risk factors for inflammatory breast cancer and other invasive breast cancers C Schairer, Y Li, P Frawley, BI Graubard, RD Wellman, DSM Buist, ... Journal of the National Cancer Institute 105 (18), 1373-1384, 2013 | 84 | 2013 |
| Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes I Poschke, Y Mao, R Kiessling, J de Boniface Journal of translational medicine 11, 1-9, 2013 | 83 | 2013 |
| The role of inflammation in inflammatory breast cancer TM Fouad, T Kogawa, JM Reuben, NT Ueno Inflammation and cancer, 53-73, 2014 | 80 | 2014 |
| Acute myeloid leukemia developing in patients with autoimmune diseases SM Ramadan, TM Fouad, V Summa, SKH Hasan, F Lo-Coco haematologica 97 (6), 805, 2012 | 78 | 2012 |
| Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC JV Heymach, D Harpole, T Mitsudomi, JM Taube, G Galffy, M Hochmair, ... Cancer Research 83 (8_Supplement), CT005-CT005, 2023 | 74 | 2023 |
| Perioperative durvalumab for resectable non–small-cell lung cancer JV Heymach, D Harpole, T Mitsudomi, JM Taube, G Galffy, M Hochmair, ... New England Journal of Medicine 389 (18), 1672-1684, 2023 | 72 | 2023 |
| Novel therapeutic strategies in the treatment of triple-negative breast cancer K Oualla, HM El-Zawahry, B Arun, JM Reuben, WA Woodward, ... Therapeutic advances in medical oncology 9 (7), 493-511, 2017 | 71 | 2017 |
| Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab for the treatment of … JV Heymach, T Mitsudomi, D Harpole, M Aperghis, S Jones, H Mann, ... Clinical Lung Cancer 23 (3), e247-e251, 2022 | 66 | 2022 |
| Optical coherence tomography accurately identifies intermediate atherosclerotic lesions—an in vivo evaluation in the rabbit carotid artery M Zimarino, F Prati, E Stabile, J Pizzicannella, T Fouad, A Filippini, ... Atherosclerosis 193 (1), 94-101, 2007 | 61 | 2007 |
| Management of breast diseases I Jatoi, M Kaufmann Springer, 2010 | 59 | 2010 |
| Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond JJ Chan, TJY Tan, RA Dent Therapeutic Advances in Medical Oncology 11, 1758835919880429, 2019 | 55 | 2019 |
Wendy WoodwardProfessor, MD Anderson Cancer CenterEmail confirmado em mdanderson.org
